Title: Anti-CdtB and anti-vinculin antibodies to diagnose irritable bowel syndrome in
inflammatory bowel disease patients
Version: 1 Date: 24 Oct 2023
Reviewer:  Ilhami Yüksel
Reviewer's report:
In this prospective observational study, the authors aimed to determine the clinical utility of
an antibody-based strategy to diagnose IBS/IBS-D in IBD patients that present with chronic
diarrhea despite endoscopic remission.
They have 4 groups, which include Active IBD, Quiescent IBD, Diarrhea-predominant irritable
bowel syndrome and Healthy controls.
In the literature, large cohort study showed that higher levels of antibodies to CdtB and vinculin
were detected in IBS-D subjects as compared to IBD subjects and healthy controls. However,
in the presented study there is no difference between diarrhea-predominant irritable bowel
syndrome and healthy controls in terms of anti-CdtB and anti-vinculin antibodies in the Brazilian
population. Therefore, in the Brazilian IBD population, such markers could not be used to
differentiate between active and quiescent IBD or between IBS and IBS-D.
Title: Anti-CdtB and anti-vinculin antibodies to diagnose irritable bowel syndrome in
inflammatory bowel disease patients
Version: 1 Date: 24 Oct 2023
Reviewer:  Ilhami Yüksel
Reviewer's report:
In this prospective observational study, the authors aimed to determine the clinical utility of
an antibody-based strategy to diagnose IBS/IBS-D in IBD patients that present with chronic
diarrhea despite endoscopic remission.
They have 4 groups, which include Active IBD, Quiescent IBD, Diarrhea-predominant irritable
bowel syndrome and Healthy controls.
In the literature, large cohort study showed that higher levels of antibodies to CdtB and vinculin
were detected in IBS-D subjects as compared to IBD subjects and healthy controls. However,
in the presented study there is no difference between diarrhea-predominant irritable bowel
syndrome and healthy controls in terms of anti-CdtB and anti-vinculin antibodies in the Brazilian
population. Therefore, in the Brazilian IBD population, such markers could not be used to
differentiate between active and quiescent IBD or between IBS and IBS-D.
Please review this paper.
user
Title: Anti-CdtB and anti-vinculin antibodies to diagnose irritable bowel syndrome in
inflammatory bowel disease patients
Version: 1 Date: 24 Oct 2023
Reviewer:  Ilhami Yüksel
Reviewer's report:
In this prospective observational study, the authors aimed to determine the clinical utility of
an antibody-based strategy to diagnose IBS/IBS-D in IBD patients that present with chronic
diarrhea despite endoscopic remission.
They have 4 groups, which include Active IBD, Quiescent IBD, Diarrhea-predominant irritable
bowel syndrome and Healthy controls.
In the literature, large cohort study showed that higher levels of antibodies to CdtB and vinculin
were detected in IBS-D subjects as compared to IBD subjects and healthy controls. However,
in the presented study there is no difference between diarrhea-predominant irritable bowel
syndrome and healthy controls in terms of anti-CdtB and anti-vinculin antibodies in the Brazilian
population. Therefore, in the Brazilian IBD population, such markers could not be used to
differentiate between active and quiescent IBD or between IBS and IBS-D.
assistant